Novo Nordisk
NVO | NYSE
$41.60
-$0.03 (-0.07%)
At close: Nov 16, 2026, 4:00 PM ET
$41.55
-$0.05 (-0.12%)
After-hours:
Nov 16, 2026, 7:56 PM ET
Novo Nordisk Company Profile
Company profile explainedCompany Profile
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Key Executives
| Name | Position |
|---|---|
| Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board |
| Maziar Mike Doustdar | President, Chief Executive Officer & Member of the Management Board |
| Karsten Munk Knudsen | Executive Vice President, Chief Financial Officer & Member of the Management Board |
| Emil Kongshøj Larsen | EVP of International Operations & Member of Management Board |
| Hong Chow | Executive Vice President of Product & Portfolio Strategy and Member of Management Board |
| Jamey Millar | Executive Vice President of US Operations & Member of Management Board |
| John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
| Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |
Novo Nordisk
| Country | Denmark |
| IPO Date | Apr 30, 1981 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 68,794 |
| CEO | Maziar Mike Doustdar |
Stock Details
| Ticker Symbol | NVO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000353278 |
| CUSIP Number | 670100205 |
| ISIN Number | US6701002056 |
| SIC Code | 2834 |
Recent News
- 12 hours ago / zacks.comNVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
- 17 hours ago / wsj.comNovo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval
- 2 days ago / reuters.comNovo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
- 4 days ago / 247wallst.comBlackstone Is Paying Up to $1.5 Billion for Pfizer’s Answer to Wegovy
- 4 days ago / prnewswire.comNovo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- 4 days ago / seekingalpha.comSCHD-Inspired 4-Factor Dividend Growth Strategy Selections For November 2026
- 4 days ago / seekingalpha.comNovo Nordisk: Better Than It Looks, But Not A Buy Yet
- 5 days ago / fool.comJPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
- 5 days ago / seekingalpha.comNovo Nordisk: Valuations Are Blind To The Upside
- 6 days ago / 247wallst.comHims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady
Add to Watchlist
Select watchlists to add or remove NVO